GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » EV-to-EBIT

Allurion Technologies (Allurion Technologies) EV-to-EBIT : -1.40 (As of May. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Allurion Technologies's Enterprise Value is $97.74 Mil. Allurion Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-69.78 Mil. Therefore, Allurion Technologies's EV-to-EBIT for today is -1.40.

The historical rank and industry rank for Allurion Technologies's EV-to-EBIT or its related term are showing as below:

ALUR' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.87   Med: -2.16   Max: -1.25
Current: -1.4

During the past 3 years, the highest EV-to-EBIT of Allurion Technologies was -1.25. The lowest was -6.87. And the median was -2.16.

ALUR's EV-to-EBIT is ranked worse than
100% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 20.82 vs ALUR: -1.40

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Allurion Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $182.17 Mil. Allurion Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-69.78 Mil. Allurion Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -38.30%.


Allurion Technologies EV-to-EBIT Historical Data

The historical data trend for Allurion Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies EV-to-EBIT Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -2.61

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only - - - -2.87 -2.61

Competitive Comparison of Allurion Technologies's EV-to-EBIT

For the Medical Devices subindustry, Allurion Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allurion Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's EV-to-EBIT falls into.



Allurion Technologies EV-to-EBIT Calculation

Allurion Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=97.742/-69.777
=-1.40

Allurion Technologies's current Enterprise Value is $97.74 Mil.
Allurion Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allurion Technologies  (NYSE:ALUR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Allurion Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-69.777/182.173494
=-38.30 %

Allurion Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $182.17 Mil.
Allurion Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allurion Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies (Allurion Technologies) Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Website
Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760